arrow
C

Charles A. Leath

University of Alabama at Birmingham
H指数:40
被引数:8,620

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hysterectomy-corrected, age-specific incidence and survival of uterine sarcomas by histotype, race and ethnicity in the United States, 2000–2019

根据子宫切除术校正、按组织学类型、种族和族裔分组的美国2000–2019年子宫肉瘤的年龄特异性发病率和生存率

2026-10-280
PRE
Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer

基于NRG GY017的局部晚期宫颈癌免疫治疗联合化疗放射治疗中的影像引导近距离放射治疗质量保证研究

2026-01-011
OAAI
Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?

卵巢癌患者接受PARPi维持治疗时的循环肿瘤DNA监测:我们能否进一步个性化治疗?

2025-11-170
PRE
Corrigendum to ‘OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer’ [Gynecol Oncol 2025 Jun 197 182–191]

勘误:‘OVATION-2:一项评估IMNN-001(IL-12基因疗法)联合新辅助化疗在 newly-diagnosed advanced epithelial ovarian cancer 患者中安全性与有效性的随机I/II期研究’ [Gynecol Oncol 2025 Jun 197 182–191]

2025-11-060
PRE
Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263)

NRG/GOG-0263随机III期临床试验中,接受初始根治性子宫切除术和盆腔淋巴结清扫术的中危、I/IIA期宫颈癌患者,辅助放疗与放化疗的患者报告结局。

2025-10-060
OAAI
Randomized Phase III Trial of Adjuvant Radiation versus Chemoradiation in Intermediate-Risk, Early-stage Cervical Cancer following Radical Hysterectomy and Lymphadenectomy: Results from NRG Oncology/GOG-263/KGOG1008

NRG Oncology/GOG-263/KGOG1008研究:在行根治性子宫切除术和淋巴结清扫术后的中危、早期宫颈癌中,比较辅助放疗与化放疗的随机III期临床试验结果

2025-09-120
PREAI
A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer

一项关于HPV16 L2E7E6融合蛋白疫苗接种后治疗HPV16+宫颈癌的随机试点研究

2025-08-200
PRE
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results

Veliparib联合一线化疗及作为卵巢癌的维持治疗:最终总生存期及疾病相关症状结果

2025-06-170
PRE
Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US (vol 19, e0307282, 2024)

宫颈癌中的健康差异:估算疾病负担的地理变化及其与美国关键社会经济和人口因素的相关性(卷19,e0307282,2024)

2025-05-200
OA
Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical Hysterectomy

低风险宫颈癌患者在接受单纯性、改良式或根治性子宫切除术后的长期生存情况

2025-05-150
OA
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial*

将三氮烯(T)整合到顺铂化疗放疗(CRT)中治疗局部晚期宫颈癌和阴道癌:NRG-GY006 III期随机试验*的结果

2025-04-010
PRE
Ovarian Cancer/Fallopian Tube Cancer/Primary PeritonealCancer, Version 3.2024Featured Updates to the NCCN Guidelines

卵巢癌/输卵管癌/原发性腹膜癌,版本3.2024 NCCN指南重点更新

2024-10-0115
PRE
Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
2023-10-017
PRE